Ramucirumab improves survival in lung cancer - Lilly

Eli Lilly and Company said that its antibody therapy, ramucirumab, has improved overall survival in patients with non-small cell lung cancer in a global Phase 3 trial. Ramucirumab inhibits the vascular endothelial growth factor receptor 2.